NCT04238962View on ClinicalTrials.gov

A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

PHASE1CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions
OverweightObesity
Interventions
DRUG

Semaglutide (administered by DV3396 pen-injector)

Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks

DRUG

Semaglutide (administered by PDS290 pen-injector)

Increasing doses of semaglutide given sc in the stomach for 7 weeks

Trial Locations (1)

10117

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY